The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer.
 
Chinedu O. Mmeje
No Relationships to Disclose
 
Austen Slade
No Relationships to Disclose
 
Rebecca Slack
No Relationships to Disclose
 
Neema Navai
No Relationships to Disclose
 
Jianjun Gao
No Relationships to Disclose
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck; NCCN; Threshold Pharmaceuticals
Research Funding - Dendreon; Genentech; Michael and Sherry Sutton Fund for Urothelial Cancer; Millennium; NIH
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Ashish M. Kamat
Honoraria - Abbott Laboratories; Photocure; Sanofi
Consulting or Advisory Role - Archimedes; Taris
Research Funding - Celgene; Endo Pharmaceuticals; FKD Therapies
 
Colin P. N. Dinney
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - FKD Therapies; Merck Sharp & Dohme
Research Funding - FKD Therapies
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Jay Bakul Shah
No Relationships to Disclose